DE69814089D1 - Verwendung von einem draflazin analog zur schmerzbehandlung - Google Patents
Verwendung von einem draflazin analog zur schmerzbehandlungInfo
- Publication number
- DE69814089D1 DE69814089D1 DE69814089T DE69814089T DE69814089D1 DE 69814089 D1 DE69814089 D1 DE 69814089D1 DE 69814089 T DE69814089 T DE 69814089T DE 69814089 T DE69814089 T DE 69814089T DE 69814089 D1 DE69814089 D1 DE 69814089D1
- Authority
- DE
- Germany
- Prior art keywords
- phenyl
- treatment
- derivative
- 4alkyl
- aminocarbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- IWMYIWLIESDFRZ-UHFFFAOYSA-N 1-[2-(4-amino-2,6-dichloroanilino)-2-oxoethyl]-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide Chemical class C1CN(CC(=O)NC=2C(=CC(N)=CC=2Cl)Cl)C(C(=O)N)CN1CCCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 IWMYIWLIESDFRZ-UHFFFAOYSA-N 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97201813 | 1997-06-16 | ||
EP97201813 | 1997-06-19 | ||
PCT/EP1998/003664 WO1998057643A1 (en) | 1997-06-16 | 1998-06-09 | Use of draflazine-analogues for treating pain |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69814089D1 true DE69814089D1 (de) | 2003-06-05 |
DE69814089T2 DE69814089T2 (de) | 2004-02-19 |
Family
ID=8228446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69814089T Expired - Fee Related DE69814089T2 (de) | 1997-06-16 | 1998-06-09 | Verwendung von einem draflazin analog zur schmerzbehandlung |
Country Status (10)
Country | Link |
---|---|
US (1) | US6403589B1 (de) |
EP (1) | EP0999840B1 (de) |
JP (1) | JP2002504134A (de) |
KR (1) | KR20010013387A (de) |
AT (1) | ATE238794T1 (de) |
AU (1) | AU8438798A (de) |
CA (1) | CA2294011A1 (de) |
DE (1) | DE69814089T2 (de) |
ES (1) | ES2199447T3 (de) |
WO (1) | WO1998057643A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU784848B2 (en) * | 1999-12-20 | 2006-07-06 | Zalicus Pharmaceuticals Ltd. | Partially saturated calcium channel blockers |
PT1539124T (pt) * | 2002-09-05 | 2018-10-22 | Vanderbilt Royalty Sub L P | Composições e kits para a remoção de compostos irritantes de superfícies corporais |
WO2004101593A1 (ja) * | 2003-05-16 | 2004-11-25 | Kissei Pharmaceutical Co., Ltd. | 5’−修飾ヌクレオシド誘導体及びその医薬用途 |
EP1865941B8 (de) * | 2005-04-01 | 2010-12-22 | Neurogesx, Inc. | Öle von capsaicinoiden und verfahren zu ihrer herstellung und verwendung |
TW201113280A (en) | 2009-07-03 | 2011-04-16 | Nensius Res As | Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the CNS |
KR101819433B1 (ko) | 2014-06-26 | 2018-01-16 | 에프. 호프만-라 로슈 아게 | 인돌린-2-온 또는 피롤로-피리딘-2-온 유도체 |
EP3371169B1 (de) | 2015-11-06 | 2019-07-17 | H. Hoffnabb-La Roche Ag | Indolin-2-on-derivate zur verwendung in der behandlung des zns und zugehöriger erkrankungen |
PE20181885A1 (es) | 2015-11-06 | 2018-12-07 | Hoffmann La Roche | Derivados de indolin-2-ona |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2368280A1 (fr) * | 1976-10-20 | 1978-05-19 | Theramex | Nouvelle composition therapeutique presentant une activite anti-agregante plaquettaire, et son procede de preparation |
US4766125A (en) * | 1981-06-23 | 1988-08-23 | Janssen Pharmaceutica N.V. | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia |
FR2513118A1 (fr) * | 1981-09-18 | 1983-03-25 | Rocador Sa | Composition pharmaceutique a base de dipyridamol et de sel d'aluminium de l'acide acetylsalicylique pour combattre l'agregation plaquettaire |
NZ223847A (en) * | 1987-04-01 | 1989-12-21 | Janssen Pharmaceutica Nv | Substituted piperazine derivatives and pharmaceutical compositions |
US5236908A (en) | 1991-06-07 | 1993-08-17 | Gensia Pharmaceuticals, Inc. | Methods of treating injury to the central nervous system |
IL108524A0 (en) | 1993-02-03 | 1994-05-30 | Gensia Inc | Imidazodiazepine analogs |
-
1998
- 1998-06-09 WO PCT/EP1998/003664 patent/WO1998057643A1/en not_active Application Discontinuation
- 1998-06-09 DE DE69814089T patent/DE69814089T2/de not_active Expired - Fee Related
- 1998-06-09 AU AU84387/98A patent/AU8438798A/en not_active Abandoned
- 1998-06-09 ES ES98934969T patent/ES2199447T3/es not_active Expired - Lifetime
- 1998-06-09 CA CA002294011A patent/CA2294011A1/en not_active Abandoned
- 1998-06-09 AT AT98934969T patent/ATE238794T1/de not_active IP Right Cessation
- 1998-06-09 EP EP98934969A patent/EP0999840B1/de not_active Expired - Lifetime
- 1998-06-09 US US09/446,140 patent/US6403589B1/en not_active Expired - Lifetime
- 1998-06-09 KR KR19997011386A patent/KR20010013387A/ko not_active Application Discontinuation
- 1998-06-09 JP JP50374399A patent/JP2002504134A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO1998057643A1 (en) | 1998-12-23 |
DE69814089T2 (de) | 2004-02-19 |
ATE238794T1 (de) | 2003-05-15 |
JP2002504134A (ja) | 2002-02-05 |
EP0999840A1 (de) | 2000-05-17 |
ES2199447T3 (es) | 2004-02-16 |
EP0999840B1 (de) | 2003-05-02 |
AU8438798A (en) | 1999-01-04 |
CA2294011A1 (en) | 1998-12-23 |
US6403589B1 (en) | 2002-06-11 |
KR20010013387A (ko) | 2001-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LV12209A (lv) | Ar fenilgrupu aizvietoti heterocikli ka ciklooksigenazes-2 inhibitori | |
EA199700135A1 (ru) | Ингибиторы клеточной адгезии | |
MXPA04000334A (es) | Compuestos de alquilamida n-(3-amino-2-hidroxi-propil) substituidos. | |
BG104599A (en) | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas | |
BG106867A (en) | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases | |
ATE538794T1 (de) | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer | |
HUP0303363A2 (hu) | Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására | |
ATE334668T1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
MY131388A (en) | Inhibitors of hiv protease useful for the treatment of aids. | |
MY129772A (en) | Crystal modification of a n-phenyl- 2 - pyrimidineamine derivative, processes for its manufacture and its use | |
ATE527022T1 (de) | Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie | |
IN2005KO00312A (de) | ||
DK0705100T3 (da) | Terapeutiske substituerede guanidiner | |
NO990662L (no) | Trombin-inhibitorer | |
NO972391L (no) | 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav | |
ATE259795T1 (de) | Carbonsäuren und acylsulfonamide, solche verbindungen enthaltende zubereitungen und behandlungsmethoden | |
NO983991L (no) | Serin-protease-inhibitorer | |
DE69814089D1 (de) | Verwendung von einem draflazin analog zur schmerzbehandlung | |
DE69918972D1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
ES2088128T3 (es) | Aminosulfonilureas inhibidoras de acat. | |
ATE332688T1 (de) | Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung | |
GB9907571D0 (en) | Compounds | |
MXPA04005809A (es) | Inhibidores de proteinas quinasas. | |
ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
DE60010934D1 (de) | Medikamente geeignet zur Behandlung von proliferativen Erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |